Adc Therapeutics Sa · NYSE:ADCT

Adc Therapeutics Sa — Q4 2023 Earnings Presentation

21 slides from Adc Therapeutics Sa's earnings presentation, Mar 13, 2024

  1. Slide 1: 4Q 2023 Earnings Call

    4Q 2023 Earnings Call March 13, 2024

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a reco

  3. Slide 3: Agenda

    Agenda Ameet Mallik 01 Chief Executive Officer Introduction Kristen Harrington-Smith 02 Chief Commercial Officer Commercial Highlights 03 Mohamed Zaki Clinical Highlights Chief Medical Officer 04 Patrick van Berkel Research Highlights Chief Scientific Officer 05 Pepe Carmona Financial Update Chief F

  4. Slide 4: 2023: Positioning the Company for Success

    2023: Positioning the Company for Success Upgraded  Management team with extensive commercial, development, and corporate expertise Organization  Board members with biotech and large pharma leadership experience; larger number of independents Enhanced ZYNLONTA  Established new go-to-market model

  5. Slide 5: Corporate and Capital Allocation Strategy Based on Twin Pillars of Hematology and Solid Tumors

    Corporate and Capital Allocation Strategy Based on Twin Pillars of Hematology and Solid Tumors Hematology Portfolio Solid Tumor Portfolio Short-Mid Term Mid-long Term KEY ASSETS ZYNLONTA  Primary focus for capital allocation  ADCT-601 (AXL) in Phase 1 in sarcoma, pancreatic cancer and NSCLC  De-r

  6. Slide 6: Advancing ZYNLONTA Development in B-Cell Lymphomas

    Advancing ZYNLONTA Development in B-Cell Lymphomas 2023 U.S. Market Value2, 5-year prevalence3 DLBCL FL MZL Current Development Areas $3.1b2, ~109 K patients $2.6b2, ~61 K patients $1.4b2, ~38 K patients  LOTIS-5 and LOTIS-7 potential to move ZYNLONTA into 2L+ DLBCL Proportion of patients by line-o

  7. Slide 7: Key Business Updates

    Key Business Updates ZYNLONTA  4Q 2023 net product revenues of $16.6M, a 17% increase compared to 3Q 2023 (loncastuximab  Deployment of new commercial model resulted in return to growth in community and academic settings tesirine-lpyl)  FY 2023 net product revenue of $69.1M, declined 8% versus pr

  8. Slide 8: ZYNLONTA Net Sales: $16.6M in 4Q 2023

    ZYNLONTA Net Sales: $16.6M in 4Q 2023 Community Academic  Majority of the opportunity for ZYNLONTA  ZYNLONTA has an important role in academic setting  Well-suited clinical profile: highly effective monotherapy  Well-positioned for patients not suited for bispecifics/ CAR-T with manageable safet

  9. Slide 9: Significant opportunity for ZYNLONTA combinations in 2L+, despite a highly evolving market

    Significant opportunity for ZYNLONTA combinations in 2L+, despite a highly evolving market ILLUSTRATIVE MARKET EVOLUTION ~40% ~60%  Despite recent advancements, a true SoC only exists in 1L and in the academic setting in 2L with CAR-T Monjuvi Monjuvi + 3L+ CAR-T ✓ BsAbs1 ZYNLONTA  Aside from CAR-T

  10. Slide 10: LOTIS-5: Developing ZYNLONTA to be the Combination Agent of Choice in Earlier Lines of Therapy

    LOTIS-5: Developing ZYNLONTA to be the Combination Agent of Choice in Earlier Lines of Therapy LOTIS-5 Overview Status and Next Steps  Patient Population: 2L+ DLBCL, ASCT ineligible • Enrollment ongoing in randomized portion; > 2/3rd patients enrolled  Summary: Ph3 confirmatory trial in combinatio

  11. Slide 11: LOTIS-7: Combining ZYNLONTA with Bispecific Antibodies

    LOTIS-7: Combining ZYNLONTA with Bispecific Antibodies (Glofitamab or Mosunetuzumab) Screening Treatment Period Period (≤28 d) (cycles of 21 days) RATIONALE  Distinct MOAs and non-overlapping toxicities, except neutropenia Glofitamab + escalating doses of ZYNLONTA Q3W1 (ZYNLONTA 90, 120, 3+3 Dose e

  12. Slide 12: ZYNLONTA IITs (Univ. of Miami) in FL and MZL

    ZYNLONTA IITs (Univ. of Miami) in FL and MZL High-risk relapsed/refractory Follicular Lymphoma Relapsed/refractory Marginal Zone Lymphoma Study: Phase 2 study of ZYNLONTA + rituximab Study: Phase 2 open-label study of ZYNLONTA Ambition: Potentially addresses unmet need of high-risk patient Ambition:

  13. Slide 13: ADCT-601: A Novel, Potent Approach to Targeting AXL

    ADCT-601: A Novel, Potent Approach to Targeting AXL ADCT-601 Structure ADCT-601 MOA Anticipated Differentiation ADCT-601  Potential best-in-class ADC against a target expressed across multiple solid tumor types with unmet medical needs Gal Nac Sp PBD  First AXL-targeted ADC conjugated to a PBD dim

  14. Slide 14: ADCT-601 targeting AXL: Rationale and Differentiation

    ADCT-601 targeting AXL: Rationale and Differentiation TARGET RELEVANCE AXL EXPRESSION1 % of cases with high % of cases with any  AXL is expressed in multiple tumor types - including NSCLC, pancreatic, AXL expression2 AXL Expression and sarcoma Sarcoma (STS) ~30% ~90%  High expression of AXL is cor

  15. Slide 15: Novel Exatecan-based ADC Platform with Potential to be Differentiated over Commercial-Stage Toxins such as DXd

    Novel Exatecan-based ADC Platform with Potential to be Differentiated over Commercial-Stage Toxins such as DXd EXATECAN V. DXD EXATECAN ADVANTAGE Exatecan DXd  Better potency  No PgP1 transport, enabling enhanced intracellular presence  Increased bystander effect, leading to more cell death and e

  16. Slide 16: Growing Portfolio of ADC Assets against High-Value Solid Tumor Targets

    Growing Portfolio of ADC Assets against High-Value Solid Tumor Targets NaPi2b Claudin-6 PSMA Undisclosed target Target description Phosphate transporter Adhesion protein Enzymatic glycoprotein Amino acid transporter NSCLC Ovarian cancer NSCLC Tumor types of interest Prostate cancer Ovarian cancer En

  17. Slide 17: Corporate Business Development Strategy for ADCT Portfolio

    Corporate Business Development Strategy for ADCT Portfolio U.S. EX-U.S. HEMATOLOGY OVERLAND ZYNLONTA, ADCT-602 JOINT VENTURE Direct Partnership Business Development to Unlock Value SOLID TUMORS ADCT-601, Research Assets Co-development & Royalty & Co-promote* Milestones to ADCT Business Development G

  18. Slide 18: 4Q 2023 Selected Financial Data (in $ millions)

    4Q 2023 Selected Financial Data (in $ millions) Cash runway expected to extend into 4Q 2025 based on current business plan Balance Sheet December 31, 2023 Cash and cash equivalents $278.6 GAAP Non-GAAP (Adjusted)* Statement of Operations 4Q 2023 % vs. 4Q 2022 4Q 2023 % vs. 4Q 2022 Product Revenues,

  19. Slide 19: Cash Runway to Support Multiple Potential Near-Term Value-Driving Catalysts

    Cash Runway to Support Multiple Potential Near-Term Value- Driving Catalysts  ZYNLONTA:  Achieve commercial brand profitability in 2024 Hematology  LOTIS-5: Complete enrollment in 2024  LOTIS-7: Dose escalation and expansion updates throughout 2024  FL and MZL IITs: Updates at medical meetings

  20. Slide 20: 4Q 2023 Earnings Call

    ™ THERAPEUTICS Innovating Science. Inspiring Hope.

  21. Slide 21: Reconciliation of GAAP to Non-GAAP Adjustments

    Reconciliation of GAAP to Non-GAAP Adjustments in $’000 4Q 2023 4Q 2022 Net loss (GAAP) (85,031) (23,344) Adjustments: Share-based compensation expense - R&D (i) 753 3,344 Share-based compensation expense - S&M (i) (571) 209 Share-based compensation expense - G&A (i) 2,038 4,791 Deerfield warrants o

ADC Therapeutics — Q4 2023 Earnings Presentation on 6ix